Loading
A phase 3 trial of Camrelizumab in cervical cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT04906993 by Jiangsu HengRui Medicine Co., Ltd., with 443 participants enrolled, started 2021-07-23 and due to reach its primary completion in 2025-06-10. Interventions recorded: camrelizumab； famitinib malate and platinum-based chemotherapy.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.